Introduction
============

Therapy-related myeloid neoplasms are recognized as a separate entity in the World Health Organization (WHO) classification of haematological diseases.[@b1-mjhid-10-1-e2018005] The incidence of therapy-related myeloid neoplasms (t-MN) continue to rise due to the relative prolongation of survival and cure related to chemo- and radio-therapy for primary malignancies, mostly breast cancer and lymphoproliferative diseases.[@b2-mjhid-10-1-e2018005]--[@b7-mjhid-10-1-e2018005] The peak occurrence time of therapy-related acute myeloid leukemia/myelodysplastic syndrome is 3 to 5 years after prior cytotoxic treatment, while the risk decreases markedly after the first decade.[@b8-mjhid-10-1-e2018005] At present, t-MN account for 10--20% of all malignant myeloid diseases.[@b9-mjhid-10-1-e2018005] Factors associated with an increased risk of t-MN include exposure to alkylating agents, topoisomerase II inhibitors, radiation therapy,[@b10-mjhid-10-1-e2018005]--[@b15-mjhid-10-1-e2018005] and older age at treatment, in addition to genetic susceptibility.[@b16-mjhid-10-1-e2018005]--[@b21-mjhid-10-1-e2018005] t-MN after anthracyclines and/or topoisomerase II inhibitors are associated with occurrence of MLL translocation at 11q23 or RUNX1/AML1 at 21q22 after a median latency of 1 to 3 years without a prodromal phase. t-MN after alkylating agents have a median latency of 4 to 10 years and are often preceded by myelodysplasia. It is associated with unbalanced chromosome 5 and 7 abnormalities, complex karyotypes, and/or TP53 mutations. After radiation treatment, the highest risk for t-MN occurrence is registered at 2 years and appears to normalize after 10 to 15 years.[@b22-mjhid-10-1-e2018005]--[@b24-mjhid-10-1-e2018005] Particularly, patients who received radiation to chest, pelvis and vertebrae for stomach, colorectal, liver, breast, endometrial, prostate, and kidney cancers seem to be at a significantly higher risk of developing t-MN.[@b24-mjhid-10-1-e2018005],[@b25-mjhid-10-1-e2018005] More recently, it came to light the potential role of various germline genetic factors in an individual's susceptibility to t-MN, particularly for those variants that alter drug metabolism such as gene NQ01, glutathione-S-transferase,[@b9-mjhid-10-1-e2018005],[@b18-mjhid-10-1-e2018005],[@b19-mjhid-10-1-e2018005],[@b26-mjhid-10-1-e2018005] as well as those involved in DNA repair pathway such as BRCA, TP53 and MDM2.[@b20-mjhid-10-1-e2018005],[@b21-mjhid-10-1-e2018005]

Clonal cytogenetic abnormalities are found in 75--90% of t-MN, and 46--70% of them are adverse karyotype including complex karyotype, deletion or loss of chromosome 5 and/or 7.[@b3-mjhid-10-1-e2018005],[@b4-mjhid-10-1-e2018005] Cytogenetics assessment is the principal prognostic factor for relapse rate and overall survival (OS).[@b27-mjhid-10-1-e2018005]--[@b29-mjhid-10-1-e2018005] The heterogeneous treatments of therapy-related myeloid neoplasms, ranging from best supportive care to intensive chemotherapy, hypomethylating agents, and allogeneic stem cell transplantation, do not allow definite conclusions on the best treatment choice, particularly for elderly patients.[@b30-mjhid-10-1-e2018005],[@b31-mjhid-10-1-e2018005] Treatment of t-MN with conventional therapy is associated with a poor outcome in terms of survival (6 months),[@b8-mjhid-10-1-e2018005],[@b32-mjhid-10-1-e2018005] remission rate (28% to 50%) and duration of the remission.[@b33-mjhid-10-1-e2018005]--[@b35-mjhid-10-1-e2018005] On the other hand, conventional chemotherapy might be a reasonable option for t-MN with favourable karyotype such as inv(16), t(16;16), t(15;17) or t(8;21), since the reported remission rate and the disease free survival are similar to those seen for the *de novo* counterpart.[@b35-mjhid-10-1-e2018005],[@b36-mjhid-10-1-e2018005] The introduction of new drugs such as azacitidine and decitabine has shown promising results in the management of t-MN with an acceptable toxicity profile also for frail patients, and with an overall response rate of approximately 40%.[@b4-mjhid-10-1-e2018005],[@b30-mjhid-10-1-e2018005],[@b31-mjhid-10-1-e2018005],[@b37-mjhid-10-1-e2018005],[@b38-mjhid-10-1-e2018005]--[@b44-mjhid-10-1-e2018005]

Allogeneic Stem Cell Transplantation for t-MN
=============================================

Allogeneic haematopoietic stem cell transplantation (HSCT) represents the only potentially curative strategy, but it is not feasible for all patients due to age, comorbidities in elderly patients, poor organ reserve and high non-relapse mortality (NRM).[@b4-mjhid-10-1-e2018005],[@b45-mjhid-10-1-e2018005] The haematopoietic cell transplantation-specific comorbidity index (HCT-CI) was developed as a sensitive tool to measure the burden of comorbidities before HSCT and to predict both the risks of NRM and the probabilities of survival after HSCT.[@b46-mjhid-10-1-e2018005] As reported by ElSawy et al.[@b47-mjhid-10-1-e2018005] in the HCT-CI validation study, the three HCT-CI risk groups with score 0, 1--2, and ≥3 result in a NRM of 14%, 23%, and 39% with a survival of 74%, 61%, and 39%, respectively. Therefore, HSCT should be offer as a reliable option to fit patients with good performance status, intermediate and poor risk karyotype with suitable and available donor.[@b9-mjhid-10-1-e2018005],[@b27-mjhid-10-1-e2018005],[@b28-mjhid-10-1-e2018005],[@b48-mjhid-10-1-e2018005]--[@b50-mjhid-10-1-e2018005] With particularly interest to t-MN, the Center of International Bone Marrow Transplantation Research (CIBMTR) and the European Group for Bone and Marrow Transplantation (EBMT) extrapolated pre-transplant factors predicting post-HSCT outcome in these patients from larges study cohorts. CIBMTR conducted a large study cohorts on t-MN and proposed a prediction model of survival after allogeneic HSCT using the following four risk factors: age older than 35 years, poor-risk cytogenetics, t-AML not in remission or advanced t-MDS, donor other than an HLA-identical sibling or a partially or well-matched unrelated donor. Five-year survival for subjects with none, 1, 2, 3, or 4 of these risk factors was 50%, 26%, 21%, 10%, and 4%, respectively.[@b27-mjhid-10-1-e2018005] Also the EBMT group[@b28-mjhid-10-1-e2018005] reported that disease stage at transplant different from complete remission, abnormal cytogenetics (excluding t(8;21), inv(16) and t(15;17)) and patients' age \>40 years are the most significant factors predicting survival, relapse rate, disease-free survival (DFS) and NRM dividing patients into three risk groups: low, intermediate and high. Overall survival for the above-mentioned groups was 62%, 33% and 24%, respectively; DFS was 58% (low), 32% (intermediate) and 20% (high); NRM was 22% (low), 37% (intermediate) and 38% (high); finally, relapse rate was 20% (low), 31% (intermediate) and 32% (high) respectively.

We performed a review of the literature on therapy-related AML/MDS submitted to allogeneic stem cell transplantation excluding AML secondary to MDS progression. Detailed results concerning cohort size, median follow up, overall survival, NRM incidence, and relapse rate are depicted in [Table 1](#t1-mjhid-10-1-e2018005){ref-type="table"}. The reported outcomes for patients submitted to HSCT for therapy-related AML/MDS are very heterogeneous. Median OS ranges from 22% to 66%, with a NRM of 21 to 58% and a relapse rate of 26% to 42%.[@b2-mjhid-10-1-e2018005],[@b27-mjhid-10-1-e2018005],[@b28-mjhid-10-1-e2018005],[@b38-mjhid-10-1-e2018005],[@b51-mjhid-10-1-e2018005]--[@b62-mjhid-10-1-e2018005]

Monocentric Observational Study
===============================

Patients and disease characteristics
------------------------------------

We retrospectively analyzed patients submitted to HSCT in our department and identified 30 patients with a diagnosis of therapy-related myeloid neoplasm (t-MN) transplanted between September 1999 and March 2017. Patients were 18 females (60%) and 12 males (40%) with a median age of 52.5 years (range, 20 to 64). Secondary neoplasm was acute myeloid leukemia (t-AML) in 19 cases (63%) and myelodysplasia (t-MDS) in 11 cases (37%). Data were collected through retrospective chart review and after institutional review board approval. The median time occurred from primary disease to t-MN occurrence was of 36.5 months (range, 4 to 190). Primary disease was hematologic in 15 cases (50%): Hodgkin's disease (n=2), non-Hodgkin's lymphoma (n=9), acute lymphoblastic leukemia (n=1), chronic lymphocytic leukemia (n=2) and acute myeloid leukemia (n=1). Fourteen patients (50%) had a previous diagnosis of solid tumor: medulloblastoma (n=1), breast (n=8), Ewing sarcoma (n=1), thyroid (n=1), bladder (n=2) and vagina/anus (n=1). One patient had a history of both haematological (non-Hodgkin's lymphoma) and solid tumor (breast). Twelve patients (40%) had been previously treated with chemotherapy, 8 patients (26.7%) with chemotherapy and autologous transplantation, 2 (6.7%) patients with radiotherapy, one patient (3.3%) with radioiodine therapy and 7 patients (23.3%) with a combination of chemo- and radiotherapy. At t-MN diagnosis all patients had received a median of 2 lines of therapy (range, 1 to 6) for their primary malignancy. All patients were free of their primary malignancies at the time of transplantation.

Revised International Prognostic Scoring System (IPSS-R)[@b63-mjhid-10-1-e2018005] was used to classify cytogenetics of t-MDS, while European Leukemia Net AML risk stratification by cytogenetics was used for AML.[@b64-mjhid-10-1-e2018005] Karyotype was available for 28 out of 30 patients. Eleven patients (36.7%) had normal karyotype, three patients (10%) had a favourable karyotype, 5 patients (16.7%) had an intermediate-risk karyotype and 9 patients (30%) had an adverse-risk karyotype. Molecular cytogenetics analyses were available for 14 out of 30 patients: FLT3/ITD+ (n=2), CBFB/MYH11 (n=1), NPM1+ (n=1), NPM1 and FLT3/ITD double positivity (n=1), no abnormalities (n=9). A detailed description of primary neoplasms, treatment for primary neoplasm and t-HN is reported in [Table 2](#t2-mjhid-10-1-e2018005){ref-type="table"}. Transplant features and outcomes are depicted in [Table 3](#t3-mjhid-10-1-e2018005){ref-type="table"}.

Statistical analysis
--------------------

Overall survival and disease-free survival (DFS) were estimated using Kaplan-Meier product method, while for curves comparison log-rank test was applied. χ^2^ test and Fisher's exact test were used to assess associations between categorical variables and OS, NRM, RRD, DFS. A competing risk analysis was performed to calculate the cumulative incidence of relapse-related death (RRD) and non-relapse mortality (NRM). For NRM, relapse was the competing event, and for relapse, NRM was the competing event. Fine and Gray's method for cumulative incidence of RRD and NRM were used to compare different groups. Statistical analysis was realized using NCSS 10. A p-value ≤ 0.05 was considered statistically significant.

Results
=======

Engraftment and GvHD
--------------------

White blood cells count of ≥1.0×10^9^/L and stable platelets count ≥20.0×10^9^/L were reached at median day +21 (range, 11 to 130) and median day +15 (range, 10 to 45), respectively. Three patients died early before achieving stable engraftment.

Acute GvHD (aGvHD)[@b65-mjhid-10-1-e2018005] occurred in 15 patients (50%) and global grading was as follows: grade I (n=3), grade II (n=5), grade III (n=6), and grade IV (n=1). Among them, three patients died because of aGvHD. Chronic GvHD (cGvHD)[@b66-mjhid-10-1-e2018005] was diagnosed in 14 out of 23 patients surviving after day +100 (65%) and global scoring was as follows: mild (n=3), moderate (n=7) and severe (n=4). One of them died for cGvHD-related complications.

Response
--------

Morphological bone marrow cytology was performed on day +30 after HSCT only in 25 patients because of early death in the others five. Three patients (12%) had a persistence of the underlying disease, whereas twenty-two patients achieved a CR (88%) on day +30. Among them, 5 patients (22.7%) experienced a relapse after a median time of 6 months (range, 3 to 15), while 17 patients (77.3%) maintained a CR after a median time of 27 months (range, 3 to 195). Median 2-ys DFS after HSCT was of 72.2% (95% CI 51.1 to 93.3) ([Figure 1A](#f1-mjhid-10-1-e2018005){ref-type="fig"}).

Overall survival, NRM and RRD
-----------------------------

At the follow up data fixed on May 2017, 13 patients were alive after a median time of 48 months (range, 3 to 195), while 17 patients died after a median time of 4 months (range, 1 to 27). The causes of death were as follows: underlying disease (n=6), GvHD (n=3), EBV-related post-transplant lymphoproliferative disease (PTLD) (n=1) and infectious complications (n=7). The overall survival at 2 years after HSCT was of 40.5% (95% CI 22.1 to 58.9), whereas the cumulative incidence of NRM and RRD at 2 years was of 44.4% (95% CI 27.6 to 71.2) and 29.6% (95% CI 15 to 58.6), respectively ([Figures 1B, 1C and 1D](#f1-mjhid-10-1-e2018005){ref-type="fig"}). No differences in terms of OS, NRM, RRD and DFS were seen stratifying patients according to underlying disease, disease status at transplant, previous treatment received, karyotype risk, patients and donor characteristics, stem cell source. An association was identified between OS and cGvHD development after HSCT, as well as between OS and relapse occurrence. Overall survival was higher in the group with cGvHD than those detected in the group without this complication (68% vs. 22%, p=0.018). Median OS was of 6 months (range, 4.6 to 7.4) in the group without cGvHD, while it was not reached in the group with cGvHD (p=0.0002, [Figure 1E](#f1-mjhid-10-1-e2018005){ref-type="fig"}). An higher mortality was recorded in the group of patients who experienced a relapse of the underlying disease as compared with patients who did not relapsed after HSCT (67% vs. 13%, p=0.011). Median OS in the group relapsed after HSCT was of 5 months (range, 2.2 to 7.8) as compared to patients without relapse, for whom a median OS was not reached (p=0.004, [Figure 1F](#f1-mjhid-10-1-e2018005){ref-type="fig"}). Relatively to NRM, an association was identified with the conditioning regimen: surprisingly, NRM was higher for patients who had received a reduced intensity conditioning as compared to those who had received a myeloablative one (p=0.046). Two-years cumulative incidence of NRM was of 74% (95% CI 49 to 100) after RIC transplant and 24% (95% CI 10 to 58) after ABL transplant (p=0.022, [Figure 1G](#f1-mjhid-10-1-e2018005){ref-type="fig"}). Finally, also for RRD an association was found with cGvHD development after HSCT: among patients with cGvHD, a minor number of RRD was recorded as compared to patients who had not developed this complication (p=0.018). The cumulative incidence of RRD at 2 years after HSCT was of 9% (95% CI 1 to 59) for patients with cGvHD and 65% (95% CI 38 to 100) for patients without cGvHD (p=0.004, [Figure 1H](#f1-mjhid-10-1-e2018005){ref-type="fig"}).

Two patients (6.7%) experienced a third tumor, in particular a breast cancer occurred thirteen years after HSCT and an EBV-related PTLD of the brain occurred eight months after HSCT.

Discussion
==========

In the last two decades, many authors published results concerning different cohorts of patients with therapy-related acute myeloid leukemia or myelodysplasia submitted to allogeneic stem cell transplantation. An high heterogeneity in the percentage of OS (22% to 66%), NRM (21% to 58%) and relapse rate (26% to 42%) come to light from these experience.[@b2-mjhid-10-1-e2018005],[@b27-mjhid-10-1-e2018005],[@b28-mjhid-10-1-e2018005],[@b38-mjhid-10-1-e2018005],[@b51-mjhid-10-1-e2018005]--[@b62-mjhid-10-1-e2018005] Each of these studies highlighted a different key point in this transplant setting, which might affect outcome after HSCT. The mainly predicting factor for OS resulted the karyotype and the recipient performance status at transplant.[@b38-mjhid-10-1-e2018005],[@b54-mjhid-10-1-e2018005],[@b56-mjhid-10-1-e2018005] Patients achieving a CR before transplantation showed better outcomes, whereas multiple therapy lines increase organ damage as well as the incidence of neutropenia, infection events and the immunosuppression of the patient increase TRM.[@b54-mjhid-10-1-e2018005],[@b60-mjhid-10-1-e2018005],[@b61-mjhid-10-1-e2018005] Patients at risk for treatment-related myeloid neoplasms should be followed closely and be considered for stem-cell transplantation early in the course of myelodysplasia.[@b38-mjhid-10-1-e2018005],[@b58-mjhid-10-1-e2018005],[@b61-mjhid-10-1-e2018005] Considering the incremented risk of relapse according to blasts percentage, patients with secondary MDS should be direct to transplantation before the progression into AML, and if secondary AML occurs, they should be transplanted as soon as possible.[@b61-mjhid-10-1-e2018005] For patients who did not achieved a CR pre-transplant, rapid transplantation, also considering alternative donor, could offer a reasonable outcome, reducing the risk of deterioration of the patient's performance status. OS after HSCT in patients aged 60 years or above was very poor.[@b50-mjhid-10-1-e2018005],[@b51-mjhid-10-1-e2018005],[@b67-mjhid-10-1-e2018005],[@b68-mjhid-10-1-e2018005] Reduced intensity conditioning and conditioning with targeted busulphan dose[@b38-mjhid-10-1-e2018005],[@b51-mjhid-10-1-e2018005],[@b58-mjhid-10-1-e2018005] might reduce TRM, especially for those patients with a reduced organ reserve. As reported for patients with de novo MDS,[@b69-mjhid-10-1-e2018005] pre-transplant disease stage, cytogenetic risk group,[@b57-mjhid-10-1-e2018005],[@b56-mjhid-10-1-e2018005] type of therapy given for the original disease, transplant conditioning regimen, and patient age[@b61-mjhid-10-1-e2018005] significantly affect relapse-free survival among patients with secondary MDS/t-AML.[@b38-mjhid-10-1-e2018005] Concerning to stem cell source, peripheral blood instead of bone marrow appeared to reduce NRM[@b38-mjhid-10-1-e2018005] and relapse rate[@b38-mjhid-10-1-e2018005],[@b57-mjhid-10-1-e2018005] and to improve OS.[@b38-mjhid-10-1-e2018005] On the other hand, controversial data were reported relative to donor source impact on OS.[@b2-mjhid-10-1-e2018005],[@b27-mjhid-10-1-e2018005],[@b38-mjhid-10-1-e2018005],[@b53-mjhid-10-1-e2018005],[@b70-mjhid-10-1-e2018005]

In our cohort, global OS appeared to fit with those reported from several authors (40.5% vs 22--66%), whereas NRM appeared the major cause of death, even if the NRM rate was comparable to others data (44% vs 21--58%).[@b2-mjhid-10-1-e2018005],[@b27-mjhid-10-1-e2018005],[@b28-mjhid-10-1-e2018005],[@b38-mjhid-10-1-e2018005],[@b51-mjhid-10-1-e2018005]--[@b62-mjhid-10-1-e2018005] Surprisingly, we observed an high DFS (72.2%) perhaps attributable to high cGvHD rate after HSCT, corresponding to an enhanced GvL effect. In fact, among patients with cGvHD a reduced RRD and an increased OS were registered. Graft-versus leukemia (GvL) effect, especially associated with chronic GvHD, improved DFS and OS also in adverse karyotype t-MN submitted to HSCT.[@b71-mjhid-10-1-e2018005] Probably due to the small size of our study group, no differences in terms of post-transplant outcomes emerged dividing patients according to recipient age, previous treatment, disease status at transplant, karyotype, donor or stem cell source. Unexpectedly, we found a higher NRM among patients who had received a RIC transplant as compared to ABL, but no differences in performance status, pre-transplant risk score or disease status existed between the two groups.

An interesting feature revealed by our curves was that DFS reached a plateau approximately after the first year post HSCT, while OS reached its prolonged plateau after the second one. In fact, no relapse was ascertained after the first year post-HSCT, so that eighteen patients (56.7%) obtained and maintained a complete remission after HSCT. On the other hand, no deaths were recorded after the second year post-HSCT, with an OS of 40.5% at the follow up time.

Conclusions
===========

The incidence of t-MN is increasing as more individuals survive treatment for a primary cancer diagnosis. At t-MN diagnosis,[@b72-mjhid-10-1-e2018005] physicians should evaluate molecular and cytogenetic risk of the disease, performance status, age and comorbidities of patients, and should start HLA-typing to timely detect a suitable donor. Older patients with poor performance status should be offered clinical trials or best supportive care. For fit patients, molecular and cytogenetics stratification is crucial. t-APL might benefit from standard first line protocols. Favorable karyotype t-MN should be treated with standard induction chemotherapy followed by high dose cytarabine consolidation course. Normal karyotype t-MN could receive standard induction chemotherapy followed by HSCT while poor molecular karyotype t-MN should be encouraged to participate in prospective clinical trials specifically designed and they should be considered early for allogeneic HCT.[@b51-mjhid-10-1-e2018005] Upfront HSCT could be offered to patients with low blast count and poor performance status.
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###### 

Results of the review: outcomes of patients with therapy-related AML/MDS submitted to HSCT.

  Author and year                                        N° of patients   Poor karyotype (%)   OS    NRM       Relapse rate   Median follow-up
  ------------------------------------------------------ ---------------- -------------------- ----- --------- -------------- ------------------
  Finke et al, 2016[@b51-mjhid-10-1-e2018005]            79               53%                  38%   23%       42%            7.5 ys
  Tang et al, 2016[@b52-mjhid-10-1-e2018005]             16               43%                  66%   13%       20%            3.3 ys
  Alam et al, 201[@b52-mjhid-10-1-e2018005]              65               50%                  34%   31%       30--36%        5.9 ys
  Liu et al, 2015[@b53-mjhid-10-1-e2018005]              30               \-                   33%   \-        34%            2 ys
  Spina et al, 2012[@b54-mjhid-10-1-e2018005]            29               59%                  37%   32%       33%            3.7 ys
  Zinke-Cerwenka et al, 2011[@b55-mjhid-10-1-e2018005]   17               47%                  47%   30%       24%            2.6 ys
  Armand et al, 2010[@b56-mjhid-10-1-e2018005]           24               50%                  41%   17%       38%            2.8 ys
  Litzow et al, 2010[@b27-mjhid-10-1-e2018005]           868              26%                  22%   48%       31%            5 ys
  Kröger et al, 2009[@b28-mjhid-10-1-e2018005]           461              42%                  35%   37%       31%            1.8 ys
  Nevill et al, 2008[@b57-mjhid-10-1-e2018005]           24               46%                  33%   30%       38%            4.5 ys
  Chang et al, 2007[@b38-mjhid-10-1-e2018005]            257              51%                  33%   54%       33--36%        3.8 ys
  Witherspoon et al, 2001[@b58-mjhid-10-1-e2018005]      111              \-                   \-    52--58%   26--40%        5 ys
  de Witte et al, 2000[@b59-mjhid-10-1-e2018005]         67               \-                   35%   46%       36%            5 ys
  Yacoub-Agha et al, 2000[@b60-mjhid-10-1-e2018005]      70               \-                   30%   49%       42%            7.9 ys
  Anderson et al, 1997[@b61-mjhid-10-1-e2018005]         46               25%                  26%   44%       33%            5 ys
  Ballen et al, 1997[@b62-mjhid-10-1-e2018005]           18               50%                  28%   50%       22%            3 ys
  This report, 2017                                      30               32%                  41%   44%       27%            2 ys

###### 

Detailed report of patients, primary and therapy-related disease and treatment.

  Patients n.   Sex      Age   First neoplasia         Treatment for first neoplasm   Time to t-MN (months)   t-MN    Blasts count %   Molecular marker   Karyotype                                                                                 Pre-HSCT treatment
  ------------- -------- ----- ----------------------- ------------------------------ ----------------------- ------- ---------------- ------------------ ----------------------------------------------------------------------------------------- --------------------
  1             Female   60    NHL                     CHT+ASCT                       18                      t-MDS   20               N.A.               46,XX                                                                                     Aza
  2             Female   53    Breast cancer           CHT+RT                         33                      t-AML   20               N.A.               Hyperploid (93--94, XX), +G, −F, +C[\*](#tfn2-mjhid-10-1-e2018005){ref-type="table-fn"}   None
  3             Female   49    Breast cancer           CHT                            32                      t-AML   23               Inv (16)           46, XX, Inv (16)                                                                          SD-CHT
  4             Female   62    NHL                     CHT+ASCT                       120                     t-MDS   N.A.             N.A.               46, XX, (−7)                                                                              Aza
  5             Female   29    Breast cancer           CHT+RT                         24                      t-AML   N.A.             N.A.               46, XX                                                                                    LD-CHT
  6\#           Male     33    AML                     CHT+ASCT                       72                      t-MDS   N.A.             N.A.               45, XY, (−7)                                                                              Aza
  7             Male     30    NHL                     CHT+ASCT                       60                      t-MDS   15               N.A.               N.A.                                                                                      None
  8             Female   57    Breast cancer           RT                             180                     t-AML   58               NPM1+              46, XX                                                                                    SD-CHT
  9             Male     48    CLL                     CHT                            37                      t-AML   20               None               46, XY, (−7)                                                                              SD-CHT
  10            Female   36    Breast cancer           CHT+RT                         48                      t-AML   90               None               46, XX                                                                                    Aza
  11            Female   56    Breast cancer and NHL   CHT+RT                         108                     t-MDS   N.A.             N.A.               46, XX, (−7)                                                                              Aza
  12            Female   48    Thyroid cancer          RIT                            4                       t-AML   20               NPM1+, FLT3+       N.A                                                                                       SD-CHT
  13            Male     48    Bludder cancer          CHT                            48                      t-AML   34               None               46, XY, t(3;3), (−7), (+8)                                                                SD-CHT
  14            Female   55    HL                      CHT                            36                      t-AML   N.A.             N.A.               N.A.                                                                                      SD-CHT
  15            Male     55    NHL                     CHT+ASCT                       144                     t-MDS   4                N.A.               46, XY                                                                                    Aza
  16            Female   57    Breast cancer           RT                             24                      t-AML   9                N.A.               46, XX, (+8)                                                                              None
  17            Male     40    ALL                     CHT                            29                      t-MDS   5                N.A.               45, XY (−7)                                                                               None
  18            Female   53    Breast cancer           CHT+RT                         120                     t-AML   N.A.             N.A.               47, XY, (−11)(q14q23)                                                                     LD-CHT
  19            Female   56    NHL                     CHT+ASCT                       24                      t-MDS   6                None               N.A.                                                                                      Aza
  20            Female   41    Ewing sarcoma           CHT                            17                      t-AML   85               None               46, XX                                                                                    SD-CHT
  21            Male     62    NHL                     CHT                            61                      t-MDS   5                N.A.               48, XXY (+8)                                                                              Aza
  22            Female   39    Breast cancer           CHT+ASCT                       30                      t-AML   N.A.             N.A.               Hypoploid (42--44, XX)                                                                    SD-CHT
  23            Female   55    NHL                     CHT+RT                         16                      t-AML   91               None               46, XX, (−16), (+13)                                                                      SD-CHT
  24            Male     53    NHL                     CHT                            39                      t-AML   20               None               46, XY                                                                                    Aza
  25            Male     57    Bludder cancer          CHT                            12                      t-AML   30               FLT3+              N.A.                                                                                      SD-CHT
  26            Male     20    Medulloblastoma         CHT                            190                     t-MDS   8                None               46, XX, (−7p), (−1p), (−5q)                                                               Aza
  27            Male     59    NHL                     CHT                            12                      t-AML   40               FLT3+              46, XY                                                                                    SD-CHT
  28            Male     64    CLL                     CHT+ASCT                       48                      t-MDS   3                N.A.               46, XY (-20)                                                                              SD-CHT
  29            Female   50    HL                      CHT                            17                      t-AML   43               None               46, XX                                                                                    SD-CHT+Aza
  30            Female   52    Vagina-anus cancer      CHT+RT                         100                     t-AML   16               N.A.               N.A.                                                                                      SD-CHT

Abbreviations: t-AML=therapy-related acute myeloid leukemia; t-MDS=therapy-related myelodysplastic syndrome; NHL=non-Hodgkin lymphoma; CLL=chronic lymphocytic leukemia; HL=Hodgkin lymphoma; ALL=acute lymphoblastic leukemia; CHT=chemotherapy; RT=radiotherapy; ASCT=autologous stem cell transplantation; Aza=azacitidine; SD-CHT=standard dose chemotherapy; LD-CHT=low dose chemotherapy; RIT: radioiodine therapy. N.A.=not available;

not otherwise specified deletion in the F group and duplication in the G and C group. \# \[Patients in question had an AML with t(8;21) as first neoplasia. Seven years after the last therapy (autologous stem cell transplantation), he developed a myelodysplasia with deletion of chromosome 7, while t(8;21) was not detected\].

###### 

Transplant for t-MN: features and outcomes.

  Patient n.   Status at HSCT   HCT-CI   Time from t-HN to HSCT (months)   HSCT year   Donor   Stem cells source   Conditioning   GvHD prophylaxis   Disease response   DFS months   GvHD (acute or chronic)   Outcome   Cause of death   Survival months
  ------------ ---------------- -------- --------------------------------- ----------- ------- ------------------- -------------- ------------------ ------------------ ------------ ------------------------- --------- ---------------- -----------------
  1            refractory       9        13                                2013        REL     PB                  RIC            CSA+MTX            relapse            5            chronic                   alive                      48
  2            untreated        4        2                                 2002        REL     PB                  MAC            CSA+MTX            remission          173          chronic                   alive                      173
  3            CR               3        6                                 2001        REL     PB                  MAC            CSA+MTX            remission          195          both                      alive                      195
  4            refractory       6        11                                2014        REL     PB                  RIC            CSA+MFA            refractory         0            acute                     dead      NRM              3
  5            refractory       3        3                                 1999        REL     PB                  MAC            CSA+MTX            relapse            6            none                      dead      RRD              6
  6            PR               4        5                                 2013        MUD     PB                  RIC            CSA+MFA+ATG        N.A.               1            acute                     dead      NRM              1
  7            untreated        4        4                                 2006        MUD     CB                  RIC            CSA+MFA+ATG        remission          135          chronic                   alive                      135
  8            CR               5        19                                2015        REL     PB                  MAC            CSA+MTX            remission          18           chronic                   alive                      18
  9            refractory       7        4                                 2013        MUD     PB                  RIC            CSA+MTX+ATG        refractory         0            none                      dead      RRD              5
  10           CR               4        9                                 2012        MUD     PB                  MAC            CSA+MTX+ATG        remission          4            both                      dead      NRM              4
  11           CR               5        11                                2012        MUD     PB                  RIC            CSA+MFA            N.A.               1            none                      dead      NRM              1
  12           CR               3        19                                2009        MUD     PB                  MAC            CSA+MTX+ATG        N.A.               1            none                      dead      NRM              1
  13           refractory       3        3                                 2007        REL     PB                  RIC            CSA+MFA            remission          6            acute                     dead      NRM              6
  14           CR               3        16                                2009        REL     PB                  MAC            CSA+MFA            remission          98           chronic                   alive                      98
  15           CR               4        26                                2011        MUD     PB                  MAC            CSA+MTX+ATG        remission          8            both                      dead      NRM              8
  16           untreated        3        2                                 2016        REL     PB                  MAC            CSA+MTX+ATG        remission          14           both                      alive                      14
  17           untreated        5        4                                 2014        MUD     BM                  MAC            CSA+MFA+ATG        remission          37           both                      alive                      37
  18           refractory       3        7                                 2004        MUD     PB                  MAC            CSA+MTX+ATG        relapse            12           none                      dead      RRD              12
  19           refractory       7        8                                 2016        HAPLO   BM                  MAC            CSA+MFA+Cy         N.A.               1            none                      dead      NRM              1
  20           CR               3        7                                 2017        HAPLO   BM                  MAC            CSA+MFA+Cy         remission          3            acute                     alive                      3
  21           PR               4        12                                2015        MUD     PB                  MAC            CSA+MTX+ATG        remission          19           both                      alive                      19
  22           refractory       3        9                                 2009        REL     PB                  MAC            CSA+MTX            refractory         0            none                      dead      RRD              4
  23           CR               3        6                                 2009        REL     PB                  MAC            CSA+MTX            remission          92           none                      alive                      92
  24           CR               5        11                                2013        MUD     PB                  MAC            CSA+MTX+ATG        relapse            15           both                      dead      RRD              16
  25           refractory       3        6                                 2009        REL     PB                  MAC            CSA+MTX            relapse            3            acute                     dead      RRD              4
  26           PR               6        14                                2014        HAPLO   BM                  MAC            CSA+MFA+Cy         remission          32           none                      alive                      32
  27           CR               3        6                                 2011        REL     PB                  RIC            CSA+MFA            remission          68           both                      alive                      68
  28           untreated        3        36                                2006        MUD     PB                  RIC            CSA+Alemtuzumab    remission          27           chronic                   dead      NRM              27
  29           refractory       5        16                                2011        MUD     PB                  RIC            CSA+MTX+ATG        N.A.               1            acute                     dead      NRM              1
  30           CR               3        7                                 2011        MUD     PB                  RIC            CSA+MFA            remission          4            acute                     dead      NRM              4

CR=complete remission; PR=partial remission; REL=match related donor; MUD=match unrelated donor; Haplo=related haploidentical donor; PB=G-CSF-primed peripheral blood stem cells; BM=un-manipulated bone marrow stem cells; CB=un-manipulated cord blood stem cells; MAC=myeloablative conditioning; RIC=reduced intensity conditioning; CSA=cyclosporine A; MTX=methotrexate; MFA=mycophenolate mofetil; ATG=anti-lymphocytes globulin; Cy=post-transplant cyclophosphamide.
